News & Updates
Excerpt from the Press Release: PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the registrational, tumor-agnostic PYNNACLE Phase 2 trial of rezatapopt (PC14586) in…
Read More
Excerpt from the Press Release: SAN DIEGO, March 27, 2024 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer…
Read More
Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Robust Fusion at 12-Months Post-ProcedureInitial Patient Results Demonstrate Marked Improvements in Pain Scores and Disability, Along with High Patient Satisfaction Ratings Excerpt from the Press Release: LOS GATOS, CA / ACCESSWIRE / March 26, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”),…
Read More
– Marks historic milestone and opens new frontier in transplantation to address kidney shortage affecting millions of patients globally – Transplant was conducted at Massachusetts General Hospital and authorized by the U.S. FDA under a single Expanded Access protocol Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–eGenesis, a biotechnology company developing human-compatible engineered organs to…
Read More
Excerpt from the Press Release: Roche and Alnylam recently announced that the Phase II KARDIA-2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) – the leading cause of cardiovascular disease worldwide – met its primary endpoint. People with mild to moderate hypertension treated with zilebesiran added to a…
Read More
Studies to Be Presented at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Excerpt from the Press Release: BOSTON, March 21, 2024 /PRNewswire/ — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham…
Read More
The deal is the third recent buyout of a radiopharmaceutical developer in recent months, following similar deals from Eli Lilly and Bristol Myers Squibb. Excerpt from the Press Release: AstraZeneca is the latest large pharmaceutical company to make a sizable bet on radiopharmaceutical drugs for cancer, agreeing on Tuesday to acquire longtime biotechnology partner Fusion…
Read More
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting Of the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response…
Read More
VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?